BICC1
Overview
BICC1 (BicC Family RNA Binding Protein 1) encodes an RNA-binding protein involved in mRNA regulation and Wnt signaling. In cancer genomics, BICC1 is notable primarily as a fusion partner of FGFR2 in cholangiocarcinoma (CCA), where in-frame FGFR2-BICC1 fusions constitutively activate FGFR2 kinase signaling.
Alterations observed in the corpus
- BICC1 is a fusion partner in FGFR2-BICC1 in-frame fusions in cholangiocarcinoma (Cluster 4, IDH-WT subtype); FGFR2 rearrangements including this fusion are exclusive to Cluster 4 (p < 0.001) and elevate FGFR2 expression, nominating FGFR-targeted therapy PMID:28667006.
- FGFR2–BICC1 is the most recurrent fusion in CHOL (5.6%) in a pan-cancer TCGA RNA-seq fusion analysis. PMID:29617662
Cancer types (linked)
- Cholangiocarcinoma (CCA): FGFR2-BICC1 is a recurrent in-frame fusion restricted to the IDH-WT / Cluster 4 molecular subtype PMID:28667006.
Co-occurrence and mutual exclusivity
- FGFR2-BICC1 fusions co-occur with other FGFR2 rearrangements (FGFR2-STK26, -TBC1D1, -WAC) in Cluster 4 CCA and are mutually exclusive with IDH1/IDH2 mutations PMID:28667006.
Therapeutic relevance
- FGFR2-BICC1 and related FGFR2 fusions identify patients potentially eligible for FGFR-targeted inhibitors; FGFR2 3′UTR-loss truncating rearrangements also discovered in the same study expand the FGFR-targetable population beyond canonical in-frame fusions PMID:28667006.
Open questions
- The relative frequency of FGFR2-BICC1 vs. other FGFR2 fusion partners and the sensitivity of each fusion class to specific FGFR inhibitors remain to be established in prospective trials.
Sources
This page was processed by crosslinker on 2026-05-15. - PMID:29617662
This page was processed by wiki-cli on 2026-05-15.